Copenhagen, 1 December 2010 - Today, NeuroSearch (NEUR) announced that the
company has appointed Karin Garre as Chief Medical Officer for the period 1
December 2010 to 31 August 2011. During her time of employment with
NeuroSearch, Karin Garre will be a member of the Executive Management and have
the overall responsibility for the company's portfolio of clinical development
programmes.
Karin Garre is trained as a medical doctor and comes from a position as Chief
Operating Officer in Azanta. Karin Garre has more than 20 years of experience
from a number of leading positions in international pharma and biotech
companies including Genmab, the Nycomed Group, Novo Nordisk, Organon and Astra.
In these positions she has held the responsibility for a broad spectrum of
functions in particular relating to clinical drug development, business
development and general management.
Patrik Dahlen, CEO of NeuroSearch, comments:
"We are very pleased with the appointment of Karin Garre, who gives us a
competent top manager to our clinical organisation and thus the requisite time
to find the exact right solution for the long term. Karin Garre holds broad
experience from several similar positions and we are confident that she has the
right profile to contribute considerably to the management of NeuroSearch."
Patrik Dahlen
CEO
Contact persons:
Patrik Dahlen, CEO, telephone: +45 4460 8214 or +45 2629 7296
Hanne Leth Hillman, Vice President, Director of Investor & Capital Market
Relations, telephone: +45 4017 5103
About NeuroSearch
NeuroSearch A/S is a leading CNS focused and European based biopharmaceutical
company listed on NASDAQ OMX Copenhagen A/S (NEUR). The company's core business
is development of novel drugs to treat diseases of the central nervous system
(CNS), and the pipeline comprises eight products in clinical development (Phase
I-III). These include Huntexil® (pridopidine), a unique orphan drug in Phase
III for the treatment of Huntington's disease, and tesofensine ready for Phase
III development as a new type of obesity treatment. NeuroSearch is also
building commercial competences with a view to market Huntexil® through an
in-house sales organisation.
NeuroSearch has a well-established drug discovery platform in the field of ion
channels and monoamine transporters, ensuring the continuous production of
novel pharmaceutical agents. The company has strategic drug discovery and
development alliances with Janssen Pharmaceutica and Eli Lilly as well as a
licence collaboration with Abbott. Further, NeuroSearch has equity interests in
a number of private companies in the Life Science industry.
